文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

抗结核药物浓度测定国际外部质量控制计划的十年结果

Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该国际外部质量控制计划每年组织两轮,向参与实验室提供加标已知浓度抗结核药物的血清或血浆样本,测定值在称量浓度80%-120%内视为准确。至2022年共31家实验室参与,覆盖13种抗结核药物及代谢物,报告1407次测定,总体83.2%准确,中位绝对不准确度为7.3%(IQR 3.3%-15.1%),利福平和异烟肼中位绝对不准确度较高(分别为10.2%和10.9%)。

要点

  • 1407次测定中83.2%准确,中位绝对不准确度7.3%(IQR 3.3%-15.1%)。
  • 利福平和异烟肼中位绝对不准确度较高,分别为10.2%和10.9%。
  • 绝对不准确度与所测药物和操作实验室相关,与浓度水平或分析技术无关。

核心结论

  • 该外部质量控制计划十年结果说明,抗结核药物浓度测定需要持续开展外部质量控制,因为每六次测定中就有一次不准确。
  • 参与该计划可提醒实验室注意此前未发现的分析问题。

研究设计与样本

  • 该研究为国际外部(实验室间)质量控制计划十年结果的描述。
  • 每年组织两轮,向参与实验室提供加标已知浓度抗结核药物的血清或血浆样本进行分析。
  • 测定值在称量浓度80%-120%内视为准确。
  • 采用混合模型线性回归评估所测药物、浓度水平、分析技术和操作实验室对绝对不准确度的影响。
  • 至2022年共31家实验室参与,纳入13种抗结核药物及代谢物,报告1407次测定。

主要发现

  • 一线抗结核药物(异烟肼、利福平、吡嗪酰胺和乙胺丁醇)占全部测定的58%。
  • 1407次测定中83.2%准确,中位绝对不准确度为7.3%(IQR 3.3%-15.1%)。
  • 绝对不准确度与所测抗结核药物和操作实验室相关,与浓度水平或所用分析技术无关。
  • 利福平和异烟肼的中位绝对不准确度相对较高,分别为10.2%和10.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Participation in an external (interlaboratory) quality control (QC) programme is an essential part of quality assurance as it provides laboratories with valuable insights into their analytical performance. We describe the 10 year results of an international QC programme for the measurement of anti-tuberculosis (TB) drugs. METHODS: Each year, two rounds were organized in which serum (or plasma) samples, spiked with known concentrations of anti-TB drugs, were provided to participating laboratories for analysis. Reported measurements within 80%-120% of weighed-in concentrations were considered accurate. Mixed model linear regression was performed to assess the effect of the measured drug, concentration level, analytical technique and performing laboratory on the absolute inaccuracy. RESULTS: By 2022, 31 laboratories had participated in the QC programme and 13 anti-TB drugs and metabolites were included. In total 1407 measurements were reported. First-line TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) represented 58% of all measurements. Overall, 83.2% of 1407 measurements were accurate, and the median absolute inaccuracy was 7.3% (IQR, 3.3%-15.1%). The absolute inaccuracy was related to the measured anti-TB drug and to the performing laboratory, but not to the concentration level or to the analytical technique used. The median absolute inaccuracies of rifampicin and isoniazid were relatively high (10.2% and 10.9%, respectively). CONCLUSIONS: The 10 year results of this external QC programme illustrate the need for continuous external QC for the measurement of anti-TB drugs for research and patient care purposes, because one in six measurements was inaccurate. Participation in the programme alerts laboratories to previously undetected analytical problems.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Stemkens R, Mouhdad C, Franssen EJF, et al. Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations. J Antimicrob Chemother. 2024. PMID: 38581098. doi:10.1093/jac/dkae105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。